A rapamycin composition for use in treating or preventing the dry or wet form of AMD comprises an effective amount of rapamycin and a pharmaceutically acceptable carrier suitable for administration to the eye or eye tissue. A therapeutically effective amount of rapamycin and a pharmaceutically acceptable carrier suitable for administration to the eye or eye tissue is used for the preparation of a medicament for the treatment or prevention of the dry or wet form of AMD in a human.